Home
RXRX
RXRX News

Latest Recursion Pharmaceuticals Inc. (RXRX) News on January 19, 2025

Is Recursion Pharmaceuticals Stock a Buy?

Motley Fool

2 days ago

Is Recursion Pharmaceuticals Stock a Buy?

Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Zacks

3 days ago

Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

MT Newswires

5 days ago

Recursion Pharmaceuticals Insider Sold Shares Worth $287,200, According to a Recent SEC Filing

Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

Zacks

9 days ago

Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

MT Newswires

11 days ago

KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating

Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA

TipRanks

11 days ago

Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA

AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips

The Wall Street Journal

11 days ago

AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips

MT Newswires

12 days ago

BofA Securities Cuts Price Target on Recursion Pharmaceuticals to $10 From $12, Maintains Neutral Rating

MT Newswires

12 days ago

Recursion Pharmaceuticals Gets Regulatory Approvals for 2 Drug Trials

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

GlobeNewswire

12 days ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

GlobeNewswire

13 days ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Is Recursion Pharmaceuticals Stock a Millionaire Maker?

Motley Fool

a month ago

Is Recursion Pharmaceuticals Stock a Millionaire Maker?

1 Artificial Intelligence (AI) Stock That Could Soar in 2025

Motley Fool

a month ago

1 Artificial Intelligence (AI) Stock That Could Soar in 2025

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

GlobeNewswire

a month ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)

Insider Monkey

a month ago

Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials

Insider Monkey

a month ago

Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials

Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers

Insider Monkey

a month ago

Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers

MT Newswires

a month ago

Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

GlobeNewswire

a month ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

MT Newswires

a month ago

Recursion Pharmaceuticals Insider Sold Shares Worth $285,600, According to a Recent SEC Filing

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘It Is Worthwhile Speculation’

Insider Monkey

a month ago

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘It Is Worthwhile Speculation’

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

GlobeNewswire

2 months ago

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One

Benzinga

2 months ago

Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One

2 Innovative Stocks That Could Deliver Outsize Returns

Motley Fool

2 months ago

2 Innovative Stocks That Could Deliver Outsize Returns

MT Newswires

2 months ago

Recursion Pharmaceuticals, Exscientia Complete Business Combination

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

GlobeNewswire

2 months ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes

Investor's Business Daily

2 months ago

Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes

MT Newswires

2 months ago

Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination

Recursion and Exscientia Shareholders Approve the Proposed Combination

GlobeNewswire

2 months ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

GlobeNewswire

2 months ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher

Simply Wall St.

2 months ago

Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates

Zacks

2 months ago

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates

Associated Press Finance

2 months ago

Recursion Pharmaceuticals: Q3 Earnings Snapshot

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

GlobeNewswire

2 months ago

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect

GuruFocus.com

2 months ago

Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect

Is Recursion Pharmaceuticals a Millionaire-Maker Stock?

Motley Fool

3 months ago

Is Recursion Pharmaceuticals a Millionaire-Maker Stock?

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

GlobeNewswire

3 months ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

Motley Fool

3 months ago

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know

Recursion Pharmaceuticals (RXRX): A Promising Small-Cap in Biotech Innovation

Insider Monkey

3 months ago

Recursion Pharmaceuticals (RXRX): A Promising Small-Cap in Biotech Innovation

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

GlobeNewswire

3 months ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

State Street Corp's Strategic Acquisition in the Biotechnology Sector

GuruFocus.com

3 months ago

State Street Corp's Strategic Acquisition in the Biotechnology Sector

Prediction: These 2 Stocks Could Soar in 2025

Motley Fool

3 months ago

Prediction: These 2 Stocks Could Soar in 2025

Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know

Cathie Wood Is Betting on This AI Stock: Is It a Buy?

Motley Fool

3 months ago

Cathie Wood Is Betting on This AI Stock: Is It a Buy?

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

Motley Fool

3 months ago

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

3 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

Motley Fool

3 months ago

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

Zacks

4 months ago

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

MT Newswires

4 months ago

Recursion Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Trial of REC-1245 in Solid Tumors, Lymphoma

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

GlobeNewswire

4 months ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk

Motley Fool

4 months ago

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

Zacks

4 months ago

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

Is Recursion Pharmaceuticals Stock a Buy?

Motley Fool

4 months ago

Is Recursion Pharmaceuticals Stock a Buy?

Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock

Insider Monkey

4 months ago

Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock

Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers

Insider Monkey

4 months ago

Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

Zacks

4 months ago

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

MT Newswires

5 months ago

Recursion Pharmaceuticals Says REC-994 Phase 2 Trial Shows Safety and Efficacy Trends

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

GlobeNewswire

5 months ago

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

AI specialist Recursion says lead drug is safe, but efficacy less clear

BioPharma Dive

5 months ago

AI specialist Recursion says lead drug is safe, but efficacy less clear

Is Recursion Pharmaceuticals a Warren Buffett Stock?

Motley Fool

5 months ago

Is Recursion Pharmaceuticals a Warren Buffett Stock?

Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies

Insider Monkey

5 months ago

Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Motley Fool

5 months ago

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Is Recursion Pharmaceuticals Stock a Buy?

Motley Fool

5 months ago

Is Recursion Pharmaceuticals Stock a Buy?

These Stocks in Nvidia's Portfolio Took a Hit in the Second Quarter

Investopedia

5 months ago

These Stocks in Nvidia's Portfolio Took a Hit in the Second Quarter

Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks

Motley Fool

5 months ago

Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks

Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move

Motley Fool

5 months ago

Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

Motley Fool

5 months ago

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

MT Newswires

5 months ago

Recursion Pharmaceuticals Insider Sold Shares Worth $343,000, According to a Recent SEC Filing

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

Benzinga

5 months ago

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

GlobeNewswire

5 months ago

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

MT Newswires

5 months ago

Recursion Pharmaceuticals, Exscientia Shares Rise as Companies Agree to Combine

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

Zacks

5 months ago

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

5 months ago

Recursion Pharmaceuticals: Q2 Earnings Snapshot

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

GlobeNewswire

5 months ago

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

GlobeNewswire

5 months ago

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Reuters

5 months ago

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

GlobeNewswire

5 months ago

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Is Recursion Pharmaceuticals a Millionaire-Maker?

Motley Fool

5 months ago

Is Recursion Pharmaceuticals a Millionaire-Maker?

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

GlobeNewswire

5 months ago

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

6 months ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks

Motley Fool

6 months ago

99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why

Zacks

6 months ago

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

Motley Fool

6 months ago

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know

Zacks

6 months ago

Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know

3 Millionaire-Maker Artificial Intelligence (AI) Stocks

Motley Fool

6 months ago

3 Millionaire-Maker Artificial Intelligence (AI) Stocks

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks

6 months ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Is Recursion Pharmaceuticals Stock a Buy?

Motley Fool

6 months ago

Is Recursion Pharmaceuticals Stock a Buy?

1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell

Motley Fool

6 months ago

1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell

These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street

Motley Fool

6 months ago

These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street

MT Newswires

6 months ago

KeyBanc Cuts Price Target on Recursion Pharmaceuticals to $12 From $16, Maintains Overweight Rating

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Zacks

6 months ago

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)

GuruFocus.com

7 months ago

Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)

MT Newswires

7 months ago

Sector Update: Health Care Stocks Mixed Premarket Thursday

MT Newswires

7 months ago

Recursion Pharmaceuticals Prices $200 Million Stock Offering

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

GlobeNewswire

7 months ago

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

MT Newswires

7 months ago

Recursion Pharmaceuticals Plans $200 Million Public Offering

Recursion Announces Proposed Offering of Class A Common Stock

GlobeNewswire

7 months ago

Recursion Announces Proposed Offering of Class A Common Stock

Share on Social Networks: